The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Otsuka Australia Pharmaceutical Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
25 result(s) found, displaying 1 to 10
-
Designation or determinationOrphan drug
-
Cancellation by sponsorRequested by Otsuka Australia Pharmaceutical Pty Ltd
-
Cancellation by sponsorRequested by Otsuka Australia Pharmaceutical Pty Ltd
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Decitabine and cedazuridine
-
Prescription medicine registrationActive ingredients: cedazuridine; decitabine.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 15 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 30 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 15 mg + 45 mg tablet blister composite pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 30 mg + 60 mg tablet blister composite pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 30 mg + 90 mg tablet blister composite pack.